Welcome to our dedicated page for Biomea Fusion news (Ticker: BMEA), a resource for investors and traders seeking the latest updates and insights on Biomea Fusion stock.
Biomea Fusion, Inc. (Nasdaq: BMEA) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for diabetes and obesity, and its news flow reflects this focus on metabolic disease. Company updates frequently center on the progress of its two main investigational programs: icovamenib, an oral covalent menin inhibitor for insulin-deficient diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist candidate for obesity and related metabolic disorders.
News items for BMEA commonly include clinical trial milestones, such as Phase II data readouts for icovamenib in type 2 diabetes, long-term follow-up results, and the initiation or advancement of studies like COVALENT-111, COVALENT-121, COVALENT-211, COVALENT-212, and GLP-131. Biomea Fusion also reports on preclinical findings, including combination data for icovamenib with GLP-1–based therapies and weight-loss and pharmacology data for BMF-650 in animal models.
Investors following BMEA news will also see corporate and financial announcements, such as quarterly financial results, cost-management updates, and underwritten offerings of common stock and warrants. The company regularly issues press releases about its participation in scientific and investor conferences, including oral presentations at diabetes and obesity meetings and fireside chats at healthcare investment conferences.
This news page aggregates these disclosures so readers can track Biomea Fusion’s clinical progress, scientific presentations, financing activities, and other material events. For those monitoring the development of investigational therapies in diabetes and obesity, the BMEA news feed offers a centralized view of the company’s reported milestones and public communications over time.
Biomea Fusion reported a net loss of $16.4 million for Q1 2022, up from $5.9 million in Q1 2021. R&D expenses surged to $11.4 million, up from $3.8 million, due to increased personnel and clinical costs for BMF-219, a novel covalent menin inhibitor. The company holds a cash position of $165.6 million. The COVALENT-101 study expands enrollment to include DLBCL and MM patients, while preclinical data supporting BMF-219's efficacy will be presented at ASCO and ADA Scientific Sessions.
Biomea Fusion (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, announced that CEO Thomas Butler will participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference. This event will occur on May 11, 2022, at 4:00 PM Pacific Time. Investors can access a live webcast of the chat, which will be available for 90 days post-presentation. Biomea Fusion focuses on developing covalent small molecules targeting genetically defined cancers and metabolic diseases, aiming to enhance treatment efficacy and patient outcomes.
Biomea Fusion, a clinical-stage biopharmaceutical company, announced the acceptance of two abstracts for the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. These abstracts focus on the preclinical activity of the irreversible Menin inhibitor, BMF-219, in chronic lymphocytic leukemia (CLL), and details of the ongoing COVALENT-101 Phase I trial involving BMF-219 for various blood cancers. The ASCO meeting will take place from June 3-7, 2022, in Chicago, IL. Biomea aims to develop covalent small molecules targeting genetically defined cancers.
Biomea Fusion, Inc. (Nasdaq: BMEA) presented promising data for its covalent menin inhibitor, BMF-219, at the AACR Annual Meeting. The drug showed significant cytotoxic activity in various preclinical models, including diffuse large B-cell lymphoma and multiple myeloma. BMF-219 demonstrated superior potency compared to existing KRAS inhibitors, achieving over 90% growth inhibition in multiple cell lines. A Phase I study (COVALENT-101) is currently enrolling patients with relapsed/refractory cancers, indicating potential for treating significant unmet needs in oncology.
Biomea Fusion (Nasdaq: BMEA) announced acceptance of a late-breaking abstract detailing preclinical data from an in vivo study of BMF-219, aimed at treating type 2 diabetes, for presentation at the American Diabetes Association's 82nd Scientific Sessions, taking place June 3-7, 2022, in New Orleans. The company focuses on developing covalent small molecules for genetically defined cancers and metabolic diseases, which may offer advantages over conventional drugs. Further details on the presentation will be disclosed following ADA's embargo policies.
Biomea Fusion, a clinical-stage biopharmaceutical company, announced its participation in the Oppenheimer 32nd Annual Virtual Healthcare Conference on March 16, 2022. CEO Thomas Butler will engage in a fireside chat at 7:00 AM Pacific Time. The company focuses on developing novel irreversible covalent small molecules aimed at treating genetically defined cancers and metabolic diseases. They utilize their proprietary FUSION™ System to advance therapeutic agents targeting key oncogenic drivers.
Investors can access the audio webcast on the company's website in the Investor Relations section.
Biomea Fusion announced the acceptance of its abstract for presentation at the upcoming American Diabetes Association Scientific Sessions, scheduled for June 3-7, 2022. The presentation will focus on preclinical data for BMF-219, a novel treatment for type 2 diabetes. The company plans to initiate a Phase I/II clinical trial of BMF-219 in the second half of 2022, pending IND application clearance. Biomea aims to develop irreversible small molecules to treat genetically defined cancers and metabolic diseases, and sees significant potential in BMF-219 as an oral treatment for diabetes.
Biomea Fusion announced promising preclinical results for its lead program, BMF-219, an irreversible covalent menin inhibitor, at the AACR Annual Meeting 2022. The data showed high potency and complete growth inhibition in high-grade B-cell lymphoma and multiple myeloma patient-derived models. BMF-219 also demonstrated strong efficacy in various KRAS-mutant cancers, showcasing advantages over the KRAS-targeted inhibitor sotorasib. Biomea plans to enroll patients in clinical trials for multiple myeloma and diffuse large B-cell lymphoma in 2022, with an IND submission for KRAS-mutant tumors anticipated by Q4 2022.
Biomea Fusion (BMEA) reported a net loss of $41.6 million for 2021, significantly up from $5.3 million in 2020, driven by increased R&D and G&A expenses. Research and development expenses soared to $28.0 million, primarily due to costs associated with BMF-219, an irreversible covalent menin inhibitor currently in a Phase I trial. The company plans to expand trials for BMF-219 into seven cancers and diabetes, anticipating a second clinical candidate announcement in mid-2022. As of year-end 2021, cash and equivalents totaled $175.7 million, supporting future initiatives.
Biomea Fusion has appointed Dr. Steve Morris as Chief Medical Officer, who previously served as a consultant since 2020. He will lead the clinical development of BMF-219, an irreversible covalent menin inhibitor currently in a Phase I trial aimed at treating patients with specific acute leukemias. Biomea plans to expand clinical studies for BMF-219 into seven tumor types and diabetes. Dr. Morris' extensive research background includes significant contributions to the understanding of oncogenes like ALK, enhancing the company's clinical prospects in oncology.